Status and phase
Conditions
Treatments
About
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
All Subjects:
Women Ages 16 to 23 Only:
Primary purpose
Allocation
Interventional model
Masking
176 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal